Cencora分销交易提振Citius股价

2025-07-15 20:56

Citius Pharmaceuticals (NASDAQ:CTXR) traded higher in the premarket on Tuesday after the company announced that its majority-owned subsidiary, Citius Oncology (NASDAQ:CTOR), reached a distribution services agreement with the medical distributor Cencora (NYSE:COR) for its lymphoma therapy, Lymphir.
Under the agreement, Cencora (NYSE:COR) is expected to become a wholesale distributor for Lymphir, an immunotherapy approved by the FDA in August 2024 for adults with relapsed or refractory cutaneous T-cell lymphoma.
The deal, which builds on an existing distribution services agreement between the two companies, is set to widen Citius Oncology's (NASDAQ:CTOR) commercial distribution network, boosting the drug’s availability upon its market entry in the U.S.
"As we move closer to the U.S. market introduction of LYMPHIR, we remain focused on disciplined execution across all key commercial readiness activities,” CEO of Citius Pharma (NASDAQ:CTXR) and Citius Oncology (NASDAQ:CTOR) Leonard Mazur remarked.

More on Citius Pharmaceuticals, Cencora, etc.